Vivos Therapeutics (NASDAQ:VVOS) CEO Kirk Huntsman joined Steve Darling from Proactive to share news the company has closed a financing giving the company plenty of runway in 2023. Huntsman telling Proactive more about the financing and a recent FDA approval also more about the company that tackling a major problem in the world, sleep apnea and snoring in adults. They do that using nonsurgical, noninvasive, oral appliance technology.
Vivos Therapeutics closes financing bringing in just under 8 million dollars to treasury
